Skip to main content

Drug Interactions between artesunate and leniolisib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

artesunate leniolisib

Applies to: artesunate and leniolisib

GENERALLY AVOID: Coadministration of leniolisib may increase plasma levels and systemic exposure to substrates of the hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1 and OATP 1B3, and/or the intestinal and hepatobiliary efflux transporter breast cancer resistance protein (BCRP). Leniolisib is an in vitro inhibitor of these transporters. However, clinical data are not available.

MANAGEMENT: According to the manufacturer of leniolisib, concomitant use with substrates of OATP 1B1, OATP 1B3, and/or BCRP should generally be avoided.

References (2)
  1. (2023) "Product Information. Joenja (leniolisib)." Pharming Healthcare Inc.
  2. (2024) "Product Information. Joenja (leniolisib)." Pharming Technologies B.V.

Switch to consumer interaction data

Drug and food interactions

Moderate

leniolisib food

Applies to: leniolisib

MONITOR: Coadministration with inhibitors of CYP450 3A4 including grapefruit or grapefruit juice may increase the plasma concentrations of leniolisib, which undergoes extensive CYP450 3A4-mediated first-pass metabolism in the gut wall and liver. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of leniolisib. Some authorities recommend to avoid grapefruit products during leniolisib treatment (UK).

References (1)
  1. (2024) "Product Information. Joenja (leniolisib)." Pharming Technologies B.V.

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer